Market Place
Sourcing Support
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US
FDA approves four oligonucleotide therapies in 2023; Novartis, GSK, Novo bet big
In the intricate world of molecular biology, oligonucleotides stand out as versatile, powerful molec
